

Three cases of recalcitrant wounds, treated with an iodophor foam dressing



Richard Simman, M.D., FACS, FACCWS

Clinical Professor, Wright State University Boonshoft School of Medicine, Dayton, OH.
Plastic and Reconstructive Surgery Director of wound care program: Jobst Vascular Institute/ProMedica Health System, Toledo, OH.

Michel H.E. Hermans, M.D.

Hermans Consulting. Doral, FL.

Introduction

Chronicity of a wound is caused by a series of linked intrinsic and extrinsic factors. Among the extrinsic factors, contamination, infection and the presence of a biofilm play a major role. Biofilm consists of a topical microbial community that makes itself "difficult to reach" and more resistant to the host immune system by the creation of its own protective exopolymeric matrix. By some, biofilm is considered as extrinsically contributing to the poor healing trends, while other consider the development and presence of a biofilm to be among the primary reasons for chronicity.^{1,2}

Biofilms have been shown to contribute to both the infection and (hyper) inflammation³ represented in the DIME acronym,⁴ and are difficult to prevent and treat. Among topical treatment options are iodine-containing compounds.

Biological mode of action

Iodine is a broad spectrum antimicrobial agent. It targets microorganisms, including: amoebic cysts, bacteria, fungi, spores, several viruses, and pro-tozoa.⁵⁻⁸ It interferes and acts on number of structures and cellular mechanisms of these organisms^{5,7,9-11} and has a certain amount of anti-inflammatory effects as well,^{7,9,12-15} while the toxicity for human cells was shown to be very low when compared to a number of other topical agents.^{16,17} Adverse effects (including those on functions of the thyroid) are rare.¹⁸

Formulations

Iodine tincture, by definition a alcohol-based solution, is a very effective antimicrobial agent but has a number side effects.^{8,9,18-21} An iodophor, a preparation containing iodine in complex with a solubilizing agent, largely does away with these side effects. An iodophor releases free iodine within the dressing from a state of equilibrium with the wound fluid present in the dressing: iodine is released from the iodophor

as iodine is being "consumed" by microorganisms^{5,22} within the dressing. This results in less dumping and a prolonged availability of the active compound, significantly improving tolerability and safety with regard to side effects.

Biofilms and iodine

In vitro data indicate iodophors can penetrate and "kill" biofilms.²³⁻²⁶ A new iodophor is based on a polyvinyl alcohol foam dressing from which iodine release is controlled and slow. Similar to other iodophors, the compound has a relatively low level of toxicity to mammalian cells²⁷ In vitro data indicate that this dressing is effective at killing clinical strains of *Pseudomonas aeruginosa* and *Staphylococcus aureus*.²⁷ The dressing's color changes from black (Figure 3c) to white upon the depletion of iodine supply (Figure 2b).

Clinical implications

The presence of a biofilm has a major negative impact on the healing of skin ulcers.^{28,29} Therefore, early intervention, aimed at prevention and treatment/removal/destruction of the biofilm is an essential step in the healing trajectory.²⁸ This is best achieved through combination therapy incorporating mechanical debridement together with topical antibiofilm agents.³⁰ The ideal antiseptic to be used for this purpose should combine a series of properties, including being active against a broad series of microorganisms, having a low potential for (acquired) resistance and being able to penetrate into eschar/necrosis and biofilm.^{8-14,31}

It should also support aspects of wound healing (including suppression or correction of hyper inflammation), have a low toxicity level, be tolerable (i.e. not painful) and being of low cost.⁸⁻¹⁴

Iodophors were shown to have among the highest success rates in attacking/preventing biofilm (re)formation and were also shown to assist in lowering the hyperinflammatory wound environment.¹⁴⁻³²

Case 1


67-year-old obese male with recurrent venous ulcers. Ulcers were very painful and previously treated for a month with calcium alginate and Unna boots. Patient refused any debridement. He was treated with weekly dressing changes using iodophor-foam and Unna boots. Ulcers almost healed in 6 weeks time (1c) and healing was complete at 10 weeks (1f).



Case 2

32-year-old morbidly obese male with a history of bilateral venous insufficiency and lymphedema. Status post traumatic non-healing ulcer to the left anterior leg, 8 months ago, failed skin graft and 5 applications of a dermal matrix with continued compression therapy and negative pressure wound therapy.

Also status post two periods of wound infections, treated with oral antibiotics. Iodophor-foam dressings, combined an Unna boot, were changed twice a week. Photos show the results two months after the initiation of treatment (2a-2c). Thereafter, treatment was changed to a silver-foam dressing with compression, with complete healing at 2 months later (2e).



Case 3

55-year-old obese male with a self-inflicted, non-healing wound on the right thigh, existing > 12 months. A biopsy was negative for malignancy and vasculitis. Status post failed skin graft with wound recurrence. Thick slough present (3a). Patient was treated with periodic debridement and application of an iodophor-foam dressing 3 times (fresh application in situ (3c) per week and as needed. The wound is healing well (3d).



Conclusion

Prevention and treatment of biofilm is essential for healing of hard-to-heal, chronic lesions. A combination therapy of debridement, if and when possible, topical antimicrobial therapy and, depending on the type of lesion, adjunct therapies, seems to offer the highest level of success. Iodophors, with their wide antibacterial spectrum, long-lasting efficacy, limited number of side effects, and suppressive effect on (hyper) inflammation, seem to be among the most appropriate agents for aggressively "attacking" biofilms and redirecting wounds to a more normal healing pathway. Here we present three cases where an iodophor foam dressing, along with other therapies, positively impacted the healing trajectory of chronic wounds.

References

1. Seth AK, Geringer MR, Gurjala AN, *et al.* Treatment of Pseudomonas aeruginosa biofilm-infected wounds with clinical wound care strategies: a quantitative study using an in vivo rabbit ear model. *Plast Reconstr Surg* 2012;129(2):262e-74e. doi: 10.1097/PRS.0b013e31823aeb3b
2. Wolcott RD, Rhoads DD, Dowd SE. Biofilms and chronic wound inflammation. *J Wound Care* 2008;17(8):333-41. doi: 10.12968/jowc.2008.17.8.30796
3. Gurjala AN, Geringer MR, Seth AK, *et al.* Development of a novel, highly quantitative in vivo model for the study of biofilm-impaired cutaneous wound healing. *Wound Repair Regen* 2011;19(3):400-10. doi: 10.1111/j.1524-475X.2011.00690.x
4. Snyder RJ, Fife C, Moore Z. Components and Quality Measures of DIME (Devitalized Tissue, Infection/Inflammation, Moisture Balance, and Edge Preparation) in Wound Care. *Adv Skin Wound Care* 2016;29(5):205-15. doi: 10.1097/01.ASW.0000482354.01988.b4
5. Fleischer W, Reimer K. Povidone-iodine in antiseptics—state of the art. *Dermatology* 1997;195 Suppl 2:3-9. doi: 10.1159/000246022
6. Jayaraja Kumar J, Jayachandran E, Hemanth Kumar Reddy C. Application of broad spectrum antiseptic povidone iodine as powerful action: a review. *J Pharm Sci Technol* 2009;1
7. Lachapelle J, Castel O, Fueyo Casado A. Antiseptics era Bact. Resist. a focus povidone iodine. *Future Med* 2013;10(579-592)
8. Ripa S, Bruno R, Reder R. Clinical applications of Povidone-Iodine as a topical antimicrobial. Handbook of Topical Antimicrobials Industrial Applications, Industrial applications in consumer products and Pharmaceuticals. New York, NY: CRC Press 2002.
9. Leaper DJ, Durani P. Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products. *Int Wound J* 2008;5(2):361-8. doi: 10.1111/j.1742-481X.2007.00406.x
10. Mangram AJ, Horan TC, Pearson ML, *et al.* Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999;20(4):250-78; quiz 79-80. doi: 10.1086/501620
11. Schreier H, Erdos G, Reimer K, *et al.* Molecular effects of povidone-iodine on relevant microorganisms: an electron-microscopic and biochemical study. *Dermatology* 1997;195 Suppl 2:111-6. doi: 10.1159/000246043
12. Al-Kaisy A, Salih Sahib A. Role of the antioxidant effect of vitamin e with vitamin C and topical povidone-iodine ointment in the treatment of burns. *Ann Burns Fire Disasters* 2005;18
13. Eming SA, Smola-Hess S, Kurschat P, *et al.* A novel property of povidone-iodine: inhibition of excessive protease levels in chronic non-healing wounds. *J Invest Dermatol* 2006;126(12):2731-3. doi: 10.1038/sj.jid.5700474
14. Konig B, Reimer K, Fleischer W, *et al.* Effects of Betaisodona on parameters of host defense. *Dermatology* 1997;195 Suppl 2:42-8. doi: 10.1159/000246029
15. Kunisada T, Yamada K, Oda S, *et al.* Investigation on the efficacy of povidone-iodine against antiseptic-resistant species. *Dermatology* 1997;195 Suppl 2:14-8. doi: 10.1159/000246025
16. van Meurs SJ, Gawlitta D, Heemstra KA, *et al.* Selection of an optimal antiseptic solution for intraoperative irrigation: an in vitro study. *J Bone Joint Surg Am* 2014;96(4):285-91. doi: 10.2106/JBJS.M.00313
17. Schmidt J, Zyba V, Jung K, *et al.* Effects of octenidine mouth rinse on apoptosis and necrosis of human fibroblasts and epithelial cells - an in vitro study. *Drug Chem Toxicol* 2018;41(2):182-87. doi: 10.1080/01480545.2017.1337124
18. Vermeulen H, Westerbos SJ, Ubbink DT. Benefit and harm of iodine in wound care: a systematic review. *J Hosp Infect* 2010;76(3):191-9. doi: 10.1016/j.jhin.2010.04.026
19. Fabreguette A, Zhi Hua S, Lasne F, *et al.* [Evaluation of the cytotoxicity of antiseptics used in current practice on cultures of fibroblasts and keratinocytes]. *Pathol Biol (Paris)* 1994;42(9):888-92.
20. Iwasawa A, Nakamura Y. [Cytotoxic effect and influence of povidone-iodine on wounds in guinea pig]. *Kansenshogaku Zasshi* 2003;77(11):948-56.
21. Teepe RG, Koebbrugge EJ, Lowik CW, *et al.* Cytotoxic effects of topical antimicrobial and antiseptic agents on human keratinocytes in vitro. *J Trauma* 1993;35(1):8-19.
22. Rackur H. New aspects of mechanism of action of povidone-iodine. *J Hosp Infect* 1985;6 Suppl A:13-23.
23. Cogan NG, Cortez R, Fauci L. Modeling physiological resistance in bacterial biofilms. *Bull Math Biol* 2005;67(4):831-53. doi: 10.1016/j.bulm.2004.11.001
24. Hill KE, Malic S, McKee R, *et al.* An in vitro model of chronic wound biofilms to test wound dressings and assess antimicrobial susceptibilities. *J Antimicrob Chemother* 2010;65(6):1195-206. doi: 10.1093/jac/dkq105
25. Phillips PL, Yang Q, Davis S, *et al.* Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. *Int Wound J* 2015;12(4):469-83. doi: 10.1111/iwj.12142
26. Thorn RM, Austin AJ, Greenman J, *et al.* In vitro comparison of antimicrobial activity of iodine and silver dressings against biofilms. *J Wound Care* 2009;18(8):343-6. doi: 10.12968/jowc.2009.18.8.43635
27. Kennedy JP, Jones CE. Antimicrobial biofilm profiles of a controlled release foam iodophor dressing. Innovations in wound healing. Key West, 2018.
28. Schultz G, Bjarnsholt T, James GA, *et al.* Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. *Wound Repair Regen* 2017;25(5):744-57. doi: 10.1111/wrr.12590
29. Woo K, Hill R, LeBlanc K, *et al.* Effect of a surfactant-based gel on patient quality of life. *J Wound Care* 2018;27(10):664-78. doi: 10.12968/jowc.2018.27.10.664
30. Schultz, Gregory PhD, *et al.* Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. *Wound Rep Reg* 2017;25:744-757
31. Sakarya S, Gunay N, Karakulak M, *et al.* Hypochlorous Acid: an ideal wound care agent with powerful microbicidal, antibiofilm, and wound healing potency. *Wounds* 2014;26(12):342-50.
32. Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, *et al.* Povidone iodine in wound healing: A review of current concepts and practices. *Int J Surg* 2017;44:260-68. doi: 10.1016/j.ijsu.2017.06.073



**We make
healthcare
run better™**

Medline Industries, LP
Three Lakes Drive, Northfield, IL 60093
Medline United States | 1-800-MEDLINE (633-5463)
medline.com | info@medline.com

Medline Canada
1-800-268-2848 | medline.ca | canada@medline.com
Medline México
01-800-831-0898 | medlinemexico.com | mexico@medline.com

Follow us    